Form 4: BVF Partners Reports Changes in Beneficial Ownership of Kymera Therapeutics
SEC Form 4
BVF Partners and related entities report changes in their beneficial ownership of Kymera Therapeutics, including the acquisition of stock options and holdings of common stock and pre-funded warrants.
Summary
- BVF Partners L.P., along with affiliated entities and Mark N. Lampert, jointly filed a Form 4 detailing changes in their beneficial ownership of Kymera Therapeutics, Inc.
- The report covers transactions related to common stock, pre-funded warrants, and stock options.
- The reporting persons include Biotechnology Value Fund, L.P. (BVF), Biotechnology Value Fund II, L.P. (BVF2), Biotechnology Value Trading Fund OS LP (Trading Fund OS), BVF Partners OS Ltd. (Partners OS), BVF I GP LLC (BVF GP), BVF II GP LLC (BVF2 GP), BVF GP Holdings LLC (BVF GPH), BVF Partners L.P. (Partners), BVF Inc., and Mark N. Lampert.
- These entities are part of a Section 13(d) group and disclaim beneficial ownership except to the extent of their pecuniary interest.
- The transactions include the acquisition of 16,000 stock options with an exercise price of $31.20, exercisable after June 18, 2024, and expiring on June 17, 2034.
- The report also details holdings of common stock and pre-funded warrants by BVF, BVF2, and Trading Fund OS.
- Gorjan Hrustanovic, a member of Partners and a director of Kymera Therapeutics, has an agreement to transfer any economic benefit from the sale of shares from exercised securities to Partners.
Sentiment
Score: 5
Explanation: This is a routine filing, so the sentiment is neutral. It simply reflects changes in ownership.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by significant shareholders and insiders, providing transparency to the market regarding their investment activities in the company.
Related Party Transactions
- Gorjan Hrustanovic, a member of Partners and a director of Kymera Therapeutics, has an agreement to transfer any economic benefit from the sale of shares from exercised securities to Partners.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the ownership structure and investment activities of BVF Partners and related entities.
Key Dates
| Date | Description |
|---|---|
| 06/18/2024 | Date of earliest transaction and grant date of stock options. |
| 06/17/2034 | Expiration date of stock options granted on 06/18/2024. |
| 08/19/2030 | Expiration date of stock options with exercise price of $20. |
| 06/15/2031 | Expiration date of stock options with exercise price of $49.1. |
| 06/14/2032 | Expiration date of stock options with exercise price of $14.18. |
| 06/14/2033 | Expiration date of stock options with exercise price of $27.67. |
| 06/28/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.